Functional recovery in parkinsonian monkeys treated with GDNF
about
The promise of neuroprotective agents in Parkinson's diseaseImaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologiesExpression and regulation of GFRalpha3, a glial cell line-derived neurotrophic factor family receptorGlial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteinsGenetic manipulation for inherited neurodegenerative diseases: myth or reality?Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brainTreating Parkinson's disease in the 21st century: can stem cell transplantation compete?Intrastriatal transplantation of adult human neural crest-derived stem cells improves functional outcome in parkinsonian ratsNoninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson's Disease.Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's DiseaseX-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor bindingTowards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans.GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's diseaseEnovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variantsCalcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamineAcupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's diseaseGDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse modelA monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeysDopamine neuron stimulating actions of a GDNF propeptideEnhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.New developments in the surgery for Parkinson's disease.Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeysCaloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.Dopamine increases glial cell line-derived neurotrophic factor in human fetal astrocytes.Ablative surgery and deep brain stimulation for Parkinson's disease.Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.Nerve growth factor induces light adaptive cellular and synaptic plasticity in the outer retina of fish.The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes.Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor ageProtection of visual functions by human neural progenitors in a rat model of retinal disease.GDNF selectively induces microglial activation and neuronal survival in CA1/CA3 hippocampal regions exposed to NMDA insult through Ret/ERK signalling.Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation.Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disordersNigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF.Parkinson's disease management: towards a new paradigm.Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseMidbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
P2860
Q21129436-E3D73EF7-D4FF-4F30-B4CF-271555618975Q24642726-6E647BDD-7685-4871-80CE-6249C0888E8DQ24682581-90521052-B40A-41C2-9321-02B3D2D13F3FQ24683773-507EEAB2-92F5-4563-98D4-467673510EBCQ26752831-22CAD020-8DC2-400C-91A6-F6EA29770784Q27002651-13C786C6-8CE2-42B5-B0E6-A8E9E8A4B480Q27024152-1FBBC4CD-9B5A-40A1-823B-D943A85871C0Q27301260-0D18CE22-BDF0-4A0E-85E0-382D71ED5BB7Q27301281-04C220AA-7291-4764-B822-345E3047E2EAQ27320553-D541B9C2-900D-41E7-94CF-F7F6C387BE13Q27739035-8F4C21F2-C3AC-47BB-87F9-40017F80B5D5Q28067169-BC7CDA4D-E25E-439E-B4CC-7F6D3D47F733Q28088320-01B01D3A-9E5F-47C0-B985-2610AE2856C5Q28139368-499498BF-46FB-45EC-ACAD-762E7126DC47Q28274130-08A046EB-CF73-4804-9918-0954478A7660Q28394023-115916BB-6881-4471-BC8A-EF8E4842B1A3Q28543023-3E3CF889-7C78-47A0-A98F-CB8C5F4DB244Q28728201-59C7624E-75B1-4C66-8ECE-0A10BB8065CFQ28748465-31C0527E-3B86-4F0D-B465-8D068CA00081Q30387126-02605BA9-4B6F-4674-B650-728F28FB4002Q30496234-8FF99EC1-9771-4D3A-A5CC-256878ECF30BQ30580687-D7E0A381-75B2-470F-9546-E4EBE4461960Q30581632-797870BA-C73D-4307-A585-0CD59AE3E6FCQ30846057-91DA8461-200E-4BD7-B517-3EEB9F27937EQ31900813-559563BC-F239-4A66-96DD-69621C4E356EQ31949243-B5ADB966-3D57-4E29-9675-001CB726C76BQ31981875-D52BD2BD-2C05-45DF-8873-AF66CF14C388Q32034638-6BE1B8D2-4590-490F-BB34-D069D3A2F296Q32063384-B79D02B0-EBE0-40BC-B25E-15AA0C69BD0EQ33183865-FE7C99F8-38DE-4D85-9696-1084ECF3894CQ33228402-54772124-0027-46D9-9F22-919229DE875AQ33280574-4BB63FA3-C8EC-4866-8CE0-5D94D0C9AED1Q33489521-2E879BD8-2882-4EA3-BD1D-46F089D58340Q33520922-C744983C-1ABA-466F-A377-D60CA53FD0DCQ33670805-ECD42C35-52BC-4848-8337-D2DD0A1A2C96Q33679788-3467E7F4-F735-46BE-A402-D6974078993CQ33684997-5EF1FE9A-D9A2-4BD4-94FE-A1629CA5C0A8Q33714139-E5946143-A9EB-44F6-AE61-BC4CA19AEC0FQ33726762-C49CEC29-26A1-40BA-B345-69C2E676BCA8Q33745707-D22A8749-CA21-4DDB-9274-5A184BE020FE
P2860
Functional recovery in parkinsonian monkeys treated with GDNF
description
1996 nî lūn-bûn
@nan
1996 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մարտին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Functional recovery in parkinsonian monkeys treated with GDNF
@ast
Functional recovery in parkinsonian monkeys treated with GDNF
@en
Functional recovery in parkinsonian monkeys treated with GDNF
@en-gb
Functional recovery in parkinsonian monkeys treated with GDNF
@nl
type
label
Functional recovery in parkinsonian monkeys treated with GDNF
@ast
Functional recovery in parkinsonian monkeys treated with GDNF
@en
Functional recovery in parkinsonian monkeys treated with GDNF
@en-gb
Functional recovery in parkinsonian monkeys treated with GDNF
@nl
prefLabel
Functional recovery in parkinsonian monkeys treated with GDNF
@ast
Functional recovery in parkinsonian monkeys treated with GDNF
@en
Functional recovery in parkinsonian monkeys treated with GDNF
@en-gb
Functional recovery in parkinsonian monkeys treated with GDNF
@nl
P50
P3181
P356
P1433
P1476
Functional recovery in parkinsonian monkeys treated with GDNF
@en
P2093
P2888
P3181
P356
10.1038/380252A0
P4011
52b7ad1758cf64af55760a9f5fd57f041980b753
P407
P577
1996-03-21T00:00:00Z
P6179
1018654441